Which has higher valuation and earnings, AXGN or MDXG?

MiMedx Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 9.26 -$15.70M -$0.64 N/A MiMedx Group $389.42M 1.42 $48.58M $0.20 18.50

Is AXGN or MDXG more profitable?

MiMedx Group has a net margin of 7.88% compared to AxoGen's net margin of -13.21%. MiMedx Group's return on equity of 21.03% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% MiMedx Group 7.88% 21.03% 15.92%

Does the media favor AXGN or MDXG?

In the previous week, AxoGen had 2 more articles in the media than MiMedx Group. MarketBeat recorded 3 mentions for AxoGen and 1 mentions for MiMedx Group. AxoGen's average media sentiment score of 0.26 beat MiMedx Group's score of 0.00 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MDXG or NVCR?

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $389.42M 1.42 $48.58M $0.20 18.50 NovoCure $674.41M 2.89 -$136.23M -$1.53 N/A

Is MDXG or NVCR more profitable?

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 7.88% 21.03% 15.92% NovoCure -25.66% -50.82% -16.48%

Does the media prefer MDXG or NVCR?

In the previous week, NovoCure had 13 more articles in the media than MiMedx Group. MarketBeat recorded 14 mentions for NovoCure and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.00 beat NovoCure's score of -0.27 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRCT or MDXG?

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than MiMedx Group. MarketBeat recorded 2 mentions for PROCEPT BioRobotics and 1 mentions for MiMedx Group. PROCEPT BioRobotics' average media sentiment score of 0.00 equaled MiMedx Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MiMedx Group (MDXG) Competitors

$3.70 -0.04 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 -0.04 (-0.95%)

As of 04:33 PM Eastern

Compare

MDXG vs. AXGN, ESTA, NVCR, PLSE, and PRCT

Should you buy MiMedx Group stock or one of its competitors? MarketBeat compares MiMedx Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiMedx Group include AxoGen (AXGN), Establishment Labs (ESTA), NovoCure (NVCR), Pulse Biosciences (PLSE), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry.

How does MiMedx Group compare to AxoGen?

AxoGen (NASDAQ:AXGN) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

MiMedx Group has a net margin of 7.88% compared to AxoGen's net margin of -13.21%. MiMedx Group's return on equity of 21.03% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
MiMedx Group	7.88%	21.03%	15.92%

MiMedx Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	9.26	-$15.70M	-$0.64	N/A
MiMedx Group	$389.42M	1.42	$48.58M	$0.20	18.50

In the previous week, AxoGen had 2 more articles in the media than MiMedx Group. MarketBeat recorded 3 mentions for AxoGen and 1 mentions for MiMedx Group. AxoGen's average media sentiment score of 0.26 beat MiMedx Group's score of 0.00 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AxoGen has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

AxoGen presently has a consensus price target of $46.50, indicating a potential upside of 12.16%. MiMedx Group has a consensus price target of $8.50, indicating a potential upside of 129.73%. Given MiMedx Group's higher possible upside, analysts clearly believe MiMedx Group is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

MiMedx Group beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Establishment Labs?

MiMedx Group (NASDAQ:MDXG) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

MiMedx Group has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

MiMedx Group presently has a consensus price target of $8.50, suggesting a potential upside of 129.73%. Establishment Labs has a consensus price target of $87.14, suggesting a potential upside of 16.44%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts plainly believe MiMedx Group is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

MiMedx Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.42	$48.58M	$0.20	18.50
Establishment Labs	$229.58M	9.59	-$51.06M	-$1.49	N/A

MiMedx Group has a net margin of 7.88% compared to Establishment Labs' net margin of -19.05%. MiMedx Group's return on equity of 21.03% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Establishment Labs	-19.05%	-218.77%	-12.31%

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MiMedx Group had 1 more articles in the media than Establishment Labs. MarketBeat recorded 1 mentions for MiMedx Group and 0 mentions for Establishment Labs. MiMedx Group's average media sentiment score of 0.00 equaled Establishment Labs'average media sentiment score.

Company	Overall Sentiment
MiMedx Group	Neutral
Establishment Labs	Neutral

Summary

MiMedx Group beats Establishment Labs on 12 of the 14 factors compared between the two stocks.

How does MiMedx Group compare to NovoCure?

MiMedx Group (NASDAQ:MDXG) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 129.73%. NovoCure has a consensus target price of $27.29, indicating a potential upside of 61.93%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities analysts plainly believe MiMedx Group is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.42	$48.58M	$0.20	18.50
NovoCure	$674.41M	2.89	-$136.23M	-$1.53	N/A

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
NovoCure	-25.66%	-50.82%	-16.48%

MiMedx Group has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, NovoCure had 13 more articles in the media than MiMedx Group. MarketBeat recorded 14 mentions for NovoCure and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.00 beat NovoCure's score of -0.27 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiMedx Group beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

76.9% of Pulse Biosciences shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to Pulse Biosciences' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
MiMedx Group	7.88%	21.03%	15.92%

Pulse Biosciences presently has a consensus target price of $30.67, indicating a potential upside of 23.46%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 129.73%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,289.18	-$72.78M	-$1.10	N/A
MiMedx Group	$389.42M	1.42	$48.58M	$0.20	18.50

In the previous week, Pulse Biosciences and Pulse Biosciences both had 1 articles in the media. Pulse Biosciences' average media sentiment score of 1.00 beat MiMedx Group's score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Positive
MiMedx Group	Neutral

Summary

MiMedx Group beats Pulse Biosciences on 11 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

PROCEPT BioRobotics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	5.24	-$95.57M	-$1.82	N/A
MiMedx Group	$389.42M	1.42	$48.58M	$0.20	18.50

MiMedx Group has a net margin of 7.88% compared to PROCEPT BioRobotics' net margin of -31.82%. MiMedx Group's return on equity of 21.03% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
MiMedx Group	7.88%	21.03%	15.92%

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than MiMedx Group. MarketBeat recorded 2 mentions for PROCEPT BioRobotics and 1 mentions for MiMedx Group. PROCEPT BioRobotics' average media sentiment score of 0.00 equaled MiMedx Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PROCEPT BioRobotics currently has a consensus target price of $41.45, suggesting a potential upside of 46.22%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 129.73%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

MiMedx Group beats PROCEPT BioRobotics on 10 of the 15 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$551.10M	$3.30B	$6.43B	$12.06B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	18.50	18.94	23.77	23.75
Price / Sales	1.42	176.07	479.87	84.46
Price / Cash	6.75	51.45	26.99	37.25
Price / Book	2.14	8.04	10.33	6.80
Net Income	$48.58M	$23.89M	$3.57B	$337.51M
7 Day Performance	3.35%	-6.00%	-1.43%	-2.59%
1 Month Performance	2.78%	2.77%	3.33%	2.02%
1 Year Performance	-42.99%	36.20%	23.49%	26.63%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	3.1107 of 5 stars	$3.70 -1.1%	$8.50 +129.7%	-42.4%	$551.10M	$389.42M	18.50	870	Positive News
AXGN AxoGen	2.425 of 5 stars	$39.45 -0.1%	$46.50 +17.9%	+291.9%	$2.10B	$238.11M	N/A	450	Positive News Analyst Downgrade Gap Down
ESTA Establishment Labs	2.1372 of 5 stars	$71.78 +1.5%	$87.14 +21.4%	+95.6%	$2.00B	$229.58M	N/A	1,004	Positive News
NVCR NovoCure	2.5386 of 5 stars	$15.73 -7.7%	$27.29 +73.4%	+0.9%	$1.97B	$674.41M	N/A	1,605	News Coverage Insider Trade
PLSE Pulse Biosciences	3.2052 of 5 stars	$24.00 -4.0%	$30.00 +25.0%	+48.1%	$1.73B	$350K	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. AXGN, ESTA, NVCR, PLSE, and PRCT

How does MiMedx Group compare to AxoGen?

Summary

How does MiMedx Group compare to Establishment Labs?

Summary

How does MiMedx Group compare to NovoCure?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Summary

How does MiMedx Group compare to PROCEPT BioRobotics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. AXGN, ESTA, NVCR, PLSE, and PRCT

How does MiMedx Group compare to AxoGen?

Is AXGN or MDXG more profitable?

Which has higher valuation and earnings, AXGN or MDXG?

Does the media favor AXGN or MDXG?

Do insiders and institutionals have more ownership in AXGN or MDXG?

Which has more risk & volatility, AXGN or MDXG?

Do analysts rate AXGN or MDXG?

Summary

How does MiMedx Group compare to Establishment Labs?

Which has more risk & volatility, MDXG or ESTA?

Do analysts prefer MDXG or ESTA?

Which has better valuation & earnings, MDXG or ESTA?

Is MDXG or ESTA more profitable?

Do insiders & institutionals hold more shares of MDXG or ESTA?

Does the media refer more to MDXG or ESTA?

Summary

How does MiMedx Group compare to NovoCure?

Do analysts prefer MDXG or NVCR?

Which has higher valuation & earnings, MDXG or NVCR?

Do institutionals & insiders have more ownership in MDXG or NVCR?

Is MDXG or NVCR more profitable?

Which has more risk and volatility, MDXG or NVCR?

Does the media prefer MDXG or NVCR?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Which has more risk and volatility, PLSE or MDXG?

Do institutionals and insiders believe in PLSE or MDXG?

Is PLSE or MDXG more profitable?

Do analysts recommend PLSE or MDXG?

Which has better valuation and earnings, PLSE or MDXG?

Does the media favor PLSE or MDXG?

Summary

How does MiMedx Group compare to PROCEPT BioRobotics?

Which has more volatility and risk, PRCT or MDXG?

Which has higher valuation and earnings, PRCT or MDXG?

Is PRCT or MDXG more profitable?

Does the media prefer PRCT or MDXG?

Do insiders & institutionals believe in PRCT or MDXG?

Do analysts rate PRCT or MDXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools